Pfizer COVID-19 VACCINE 90 PERCENT EFFECTIVE IN PHASE 3 TRIAL

Highlights

• Albert Bourla, Chairman and CEO of Pfizer said “The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19.” 

• Pfizer said the results of its COVID-19 vaccine candidate developed with BioNTech was 90 percent effective in preventing coronavirus infections in the first round of Phase 3 trials